Login / Signup

Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial.

Axel Stenmark TullbergMartin SjöströmLena TranEmma NiméusFredrika KillanderAnikó KovácsDan LundstedtErik HolmbergPer Karsson
Published in: Journal for immunotherapy of cancer (2023)
Integrating histological grade and immunological biomarkers can identify tumors with aggressive characteristics but a low risk of IBTR despite a lack of RT boost and systemic therapy. Among high-risk tumors, the risk reduction of IBTR conferred by an activated immune infiltrate is comparable to treatment with RT. These findings may apply to cohorts dominated by estrogen receptor-positive tumors.
Keyphrases
  • estrogen receptor
  • early breast cancer
  • early stage
  • radiation therapy
  • squamous cell carcinoma
  • mesenchymal stem cells
  • locally advanced
  • radiation induced
  • cell therapy
  • smoking cessation